M. J. Campbell

This study identifies RARγ's role in bookmarking AR enhancer interactions in prostate cancer, showing its impact on enzalutamide sensitivity and lineage plasticity.

This study identifies immune microenvironment features and myoepithelial continuity as key determinants of progression in high-risk DCIS.

This study shows that combining a novel ERβ ligand with Enzalutamide reduces MYC signaling and growth in advanced prostate cancer.

This study identifies ONECUT2 as a master transcription factor that drives resistance in prostate cancer through multiple mechanisms, including activation of neuroendocrine and adenocarcinoma variants, and shows that its inhibition can suppress treatment-resistant lineage plasticity.

This study identifies an acidic dipeptide in NIS that mediates AP2 binding, showing chloroquine enhances NIS membrane retention and RAI uptake in thyroid cancer.

This study shows that sarA mutation reduces virulence in S. aureus osteomyelitis by increasing protease production, highlighting its key role in limiting protease output and maintaining virulence.

The paper analyzes VDR genomic interactions in African American prostate cancer cells and identifies BAZ1A as a regulator of VDR-dependent transcriptional responses.

This study investigates the synergistic cytoprotective effects of gypenosides and Costus pictus extract on BRIN-BD11 β-cells against palmitate and cytokine-induced toxicity.

This study shows reduced NCOR2 expression accelerates androgen deprivation therapy failure in prostate cancer by promoting DNA hypermethylation and neuroendocrine gene expression.

This study identifies germline genetic variants associated with immune traits in cancer, revealing their impact on the tumor immune microenvironment.

This study identifies ARF4 and VCP as regulators of NIS trafficking and shows FDA-approved VCP inhibitors enhance radioiodine uptake in thyroid cancer cells and mice.

This study identifies miR-96 as a regulator of RARγ expression, which in turn controls androgen signaling and prostate cancer progression through gene network alterations.